Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
-NHF and Community News
 Industry News
 Travel Advisory

 

 

 
New MASAC Recommendations Issued
 

The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) issued the following recommendations at its last meeting in Chicago, IL, on April 17, 2008. The documents were adopted by NHF’s Board of Directors on June 15, 2008.

MASAC Document #180:
MASAC Endorsement of the NHLBI Consensus Guidelines on the Diagnosis and Treatment of von Willebrand Disease
In this document, MASAC acknowledges the importance and utility of “The Diagnosis, Evaluation and Management of von Willebrand Disease,” a recent publication from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The NHLBI publication is based on the efforts of a consensus panel of experts in the field of hemostasis disorders. The purpose of convening the panel was to develop a document summarizing the current body of knowledge regarding the diagnosis and treatment of individuals with von Willebrand disease and to define areas for improvement. 

MASAC Document #181:
MASAC Recommendations Regarding Standards of Service for Pharmacy Providers of Clotting Factor Concentrates for Home Use to Patients with Bleeding Disorders
In this document, MASAC stresses the fact that patients with hemophilia and other bleeding disorders often experience unpredictable and spontaneous bleeds, and that pharmacy providers of factor products need to consider this reality when responding to requisite changes in treatment frequency and dosing. The document was issued as a means of establishing a minimum “standards of service” for U.S. pharmacy providers in meeting the unique needs of individuals with bleeding disorders.

MASAC Document #182:
MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders
This document is MASAC’s primary treatment recommendation, covering hemophilia A and B, von Willebrand disease and other congenital bleeding disorders. Included are guidelines on available U.S. therapies, vaccinations and blood product safety, as well as recommendations to the U.S. Food and Drug Administration.     

To view these documents click the links above or review the complete list of current MASAC recommendations. To request a hard copy of any current recommendation please contact HANDI, NHF’s information resource center: handi@hemophilia.org or 1.800.42.HANDI.

 

 

This section of our Web site is sponsored by: